K
5.67
-0.18 (-3.08%)
| Penutupan Terdahulu | 5.85 |
| Jumlah Dagangan | 640,170 |
| Harga / Buku (P/B) | 2.10 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.24 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.10% |
| Nisbah Semasa (MRQ) | 7.44 |
| Aliran Tunai Operasi (OCF TTM) | -133.64 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -80.19 M |
| Pulangan Atas Aset (ROA TTM) | -31.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Kyverna Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.0 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.04 |
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 12.04% |
| % Dimiliki oleh Institusi | 68.57% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gordonmd Global Investments Lp | 30 Jun 2026 | 4,244,818 |
| Gilead Sciences, Inc. | 30 Jun 2026 | 4,126,119 |
| Aigh Capital Management Llc | 30 Jun 2026 | 2,795,797 |
| Insight Holdings Group, Llc | 30 Jun 2026 | 989,054 |
| Propel Bio Management, Llc | 30 Jun 2026 | 883,198 |
| Woodline Partners Lp | 30 Jun 2026 | 845,325 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |